Randomized Controlled Trial of Oral Tranexamic Acid Intervention for the Prevention of Type II Endoleak after Endovascular Abdominal Aneurysm Repair.

IF 1.1 4区医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS

Annals of Thoracic and Cardiovascular Surgery Pub Date : 2022-08-20 Epub Date: 2022-07-05 DOI:10.5761/atcs.oa.22-00100

Yusuke Imaeda, Hiroyuki Ishibashi, Yuki Orimoto, Yuki Maruyama, Hiroki Mitsuoka, Takahiro Arima

{"title":"Randomized Controlled Trial of Oral Tranexamic Acid Intervention for the Prevention of Type II Endoleak after Endovascular Abdominal Aneurysm Repair.","authors":"Yusuke Imaeda, Hiroyuki Ishibashi, Yuki Orimoto, Yuki Maruyama, Hiroki Mitsuoka, Takahiro Arima","doi":"10.5761/atcs.oa.22-00100","DOIUrl":null,"url":null,"abstract":"Purpose: The purpose of this study was to evaluate tranexamic acid (TA) for the prevention of type II endoleak (EL2) at a high level of evidence by a randomized controlled trial.Methods: Patients who underwent endovascular aneurysm repair (EVAR) between May 2017 and January 2020 were included. Patients in the TA group were given 750 mg of TA daily for a month after EVAR. The incidence of EL2, blood coagulation/fibrinolytic ability, and changes in aneurysm diameter were compared between two groups.Result: On the 7th day after EVAR, EL2 was found in 14 patients (34.1%) in the TA group and in 7 patients (15.9%) in the non-TA group. It was also found in 12 patients (29.3%) in the TA group and 6 patients (13.6%) in the non-TA group at 1 month after EVAR. There was no significant difference in the incidence of EL2 between the two groups (p = 0.051, 0.08). Blood tests revealed that fibrin degradation product and D-dimer were significantly suppressed in the TA group, there was no significant difference in the change of diameter regardless of the TA intake.Conclusion: This study proved anti-fibrinolytic effect of the TA, but it alone had not enough power to decrease EL2 after EVAR.","PeriodicalId":8037,"journal":{"name":"Annals of Thoracic and Cardiovascular Surgery","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2022-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7e/58/atcs-28-286.PMC9433891.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Thoracic and Cardiovascular Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5761/atcs.oa.22-00100","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/5 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The purpose of this study was to evaluate tranexamic acid (TA) for the prevention of type II endoleak (EL2) at a high level of evidence by a randomized controlled trial.

Methods: Patients who underwent endovascular aneurysm repair (EVAR) between May 2017 and January 2020 were included. Patients in the TA group were given 750 mg of TA daily for a month after EVAR. The incidence of EL2, blood coagulation/fibrinolytic ability, and changes in aneurysm diameter were compared between two groups.

Result: On the 7th day after EVAR, EL2 was found in 14 patients (34.1%) in the TA group and in 7 patients (15.9%) in the non-TA group. It was also found in 12 patients (29.3%) in the TA group and 6 patients (13.6%) in the non-TA group at 1 month after EVAR. There was no significant difference in the incidence of EL2 between the two groups (p = 0.051, 0.08). Blood tests revealed that fibrin degradation product and D-dimer were significantly suppressed in the TA group, there was no significant difference in the change of diameter regardless of the TA intake.

Conclusion: This study proved anti-fibrinolytic effect of the TA, but it alone had not enough power to decrease EL2 after EVAR.

Abstract Image

查看原文本刊更多论文

口服氨甲环酸干预预防血管内动脉瘤修复术后II型腔漏的随机对照试验。

目的:本研究的目的是通过一项随机对照试验，在高证据水平上评价氨甲环酸(TA)预防II型肠内漏(EL2)的作用。方法:纳入2017年5月至2020年1月期间接受血管内动脉瘤修复(EVAR)的患者。TA组患者在EVAR后一个月内每天给予750mg TA。比较两组患者EL2发生率、凝血/纤溶能力及动脉瘤直径变化。结果:EVAR后第7天，TA组14例(34.1%)出现EL2，非TA组7例(15.9%)出现EL2。在EVAR后1个月，TA组有12例(29.3%)，非TA组有6例(13.6%)。两组EL2发生率比较，差异无统计学意义(p = 0.051, 0.08)。血液检查显示，TA组纤维蛋白降解产物和d -二聚体明显受到抑制，无论TA摄入量如何，其直径变化无显著差异。结论:本研究证实TA有抗纤溶作用，但单独使用TA不足以降低EVAR术后EL2。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Thoracic and Cardiovascular Surgery CARDIAC & CARDIOVASCULAR SYSTEMS-SURGERY

CiteScore

2.80

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： Information not localized